CA2669696A1 - Stabilized maml peptides and uses thereof - Google Patents

Stabilized maml peptides and uses thereof Download PDF

Info

Publication number
CA2669696A1
CA2669696A1 CA002669696A CA2669696A CA2669696A1 CA 2669696 A1 CA2669696 A1 CA 2669696A1 CA 002669696 A CA002669696 A CA 002669696A CA 2669696 A CA2669696 A CA 2669696A CA 2669696 A1 CA2669696 A1 CA 2669696A1
Authority
CA
Canada
Prior art keywords
polypeptide
alkyl
amino acids
modified polypeptide
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002669696A
Other languages
English (en)
French (fr)
Inventor
James Bradner
Raymond Moellering
Gregory L. Verdine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Harvard University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2669696A1 publication Critical patent/CA2669696A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CA002669696A 2006-11-15 2007-11-15 Stabilized maml peptides and uses thereof Abandoned CA2669696A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85937906P 2006-11-15 2006-11-15
US60/859,379 2006-11-15
PCT/US2007/084838 WO2008061192A2 (en) 2006-11-15 2007-11-15 Stabilized maml peptides and uses thereof

Publications (1)

Publication Number Publication Date
CA2669696A1 true CA2669696A1 (en) 2008-05-22

Family

ID=39402481

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002669696A Abandoned CA2669696A1 (en) 2006-11-15 2007-11-15 Stabilized maml peptides and uses thereof

Country Status (6)

Country Link
US (1) US9074009B2 (enExample)
EP (3) EP2091552A4 (enExample)
JP (2) JP2010510236A (enExample)
AU (1) AU2007319193A1 (enExample)
CA (1) CA2669696A1 (enExample)
WO (1) WO2008061192A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
EP2091552A4 (en) 2006-11-15 2010-01-06 Dana Farber Cancer Inst Inc STABILIZED MAML-PEPTIDES AND ITS USES
EP3170835A1 (en) * 2006-12-14 2017-05-24 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US7981998B2 (en) * 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2564862B1 (en) * 2007-02-23 2017-08-02 Aileron Therapeutics, Inc. Substituted amino acids for preparing triazole linked macrocyclic peptides
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
WO2010011313A2 (en) 2008-07-23 2010-01-28 President And Fellows Of Harvard College Ligation of stapled polypeptides
WO2010034032A2 (en) 2008-09-22 2010-03-25 Aileron Therapeutic, Inc. Methods for preparing purified polypeptide compositions
CA2737918A1 (en) * 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN102482336B (zh) * 2008-09-22 2015-05-06 爱勒让治疗公司 拟肽大环化合物
JP2012509902A (ja) * 2008-11-24 2012-04-26 エルロン・セラピューティクス・インコーポレイテッド 改善された特性を有するペプチド模倣大環状分子
WO2010083347A2 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2011008260A2 (en) 2009-07-13 2011-01-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
CA2774973A1 (en) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
RU2016111360A (ru) 2010-08-13 2018-11-27 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы
US8957026B2 (en) * 2010-09-22 2015-02-17 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
WO2012174423A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized polypeptides as regulators of rab gtpase function
EP2721061A4 (en) * 2011-06-17 2014-11-05 Harvard College VARIANT STABILIZED MAML-PEPTIDES AND USES THEREOF
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
RU2017145921A (ru) 2012-02-15 2019-02-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
EP2920197B1 (en) 2012-09-26 2021-03-17 President and Fellows of Harvard College Proline-locked stapled peptides and uses thereof
US20150225471A1 (en) 2012-10-01 2015-08-13 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
CN104812384B (zh) 2012-11-01 2020-09-18 爱勒让治疗公司 二取代的氨基酸及其制备和使用方法
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
JP6568515B2 (ja) * 2013-03-13 2019-08-28 プレジデント アンド フェローズ オブ ハーバード カレッジ ステープルドおよびステッチドポリペプチドならびにその使用
MX2015017274A (es) 2013-06-14 2016-08-04 Harvard College Moduladores del receptor del polipéptido insulina estabilizados.
EP3131922B1 (en) 2014-04-17 2020-05-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides and uses thereof for reducing cd95-mediated cell motility
JP6759109B2 (ja) 2014-05-21 2020-09-23 プレジデント アンド フェローズ オブ ハーバード カレッジ Ｒａｓ抑制性ペプチドおよびその使用
MX389354B (es) 2014-09-24 2025-03-20 Aileron Therapeutics Inc Macrociclos peptidomimeticos y formulaciones de los mismos.
JP2017533889A (ja) 2014-09-24 2017-11-16 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3310373A4 (en) 2015-06-22 2019-02-13 University of Utah Research Foundation Thiol-ene based peptide stapling and uses thereof
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
US11034720B2 (en) 2016-07-17 2021-06-15 University Of Utah Research Foundation Thiol-yne based peptide stapling and uses thereof
SG11202001162TA (en) 2017-09-07 2020-03-30 Fog Pharmaceuticals Inc Agents modulating beta-catenin functions and methods thereof
US20200408746A1 (en) * 2018-03-14 2020-12-31 Dana-Farber Cancer Institute, Inc. Stabilized Peptides for Biomarker Detection
KR20210060482A (ko) 2018-08-20 2021-05-26 포그 파마슈티컬스 인코포레이티드 펩티드의 컬렉션, 펩티드 작용제 및 이의 사용 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0633933A1 (en) 1992-03-23 1995-01-18 Imperial Cancer Research Technology Limited Leucine zippers
US5811515A (en) * 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
ES2297861T3 (es) 1996-07-12 2008-05-01 Mcgill University Compuestos y metodos para modular la adhesion celular.
US5851775A (en) 1997-03-20 1998-12-22 Johns Hopkins University β-catenin, Tcf-4, and APC interact to prevent cancer
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6277824B1 (en) * 1998-07-10 2001-08-21 Adherex Technologies Compounds and methods for modulating adhesion molecule function
US7192713B1 (en) * 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
CA2284459C (en) * 1999-10-04 2012-12-11 Neokimia Inc. Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
WO2001053331A2 (en) * 2000-01-24 2001-07-26 Adherex Technologies, Inc. Peptidomimetic modulators of cell adhesion
US7214488B2 (en) * 2001-07-03 2007-05-08 United States Of America, Represented By The Secretary, Department Of Health And Human Services Detection of MECT1-MAML2 fusion products
CN103467588B (zh) * 2003-11-05 2016-12-28 达纳-法伯癌症研究所股份有限公司 稳定的α螺旋肽及其用途
WO2005118620A2 (en) 2004-05-27 2005-12-15 New York University Methods for preparing internally constraied peptides and peptidomimetics
DE102004033312A1 (de) * 2004-07-08 2006-01-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren
EP1765378B1 (en) 2004-07-12 2014-04-16 Medical Research Fund of Tel Aviv Sourasky Medical Center Agent capable of downregulating an msf-a-dependent hif-1a and use thereof in cancer treatment
EP2091552A4 (en) 2006-11-15 2010-01-06 Dana Farber Cancer Inst Inc STABILIZED MAML-PEPTIDES AND ITS USES
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
EP3170835A1 (en) 2006-12-14 2017-05-24 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
EP2564862B1 (en) 2007-02-23 2017-08-02 Aileron Therapeutics, Inc. Substituted amino acids for preparing triazole linked macrocyclic peptides
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
WO2009110952A2 (en) * 2007-12-31 2009-09-11 New York University Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices
CN104474529A (zh) 2008-02-08 2015-04-01 爱勒让治疗公司 治疗性的拟肽大环化合物
US20110144303A1 (en) * 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
WO2009126292A2 (en) * 2008-04-08 2009-10-15 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
JP2012503013A (ja) * 2008-09-18 2012-02-02 ニューヨーク ユニバーシティ ＨＩＦ−１αと水素結合代替ヘリックスを有するｐ３００／ＣＢＰの間の相互作用の阻害
KR101754799B1 (ko) * 2010-03-26 2017-07-07 삼성전자주식회사 화소 회로, 이를 포함하는 디스플레이 장치 및 디스플레이 장치의 구동방법

Also Published As

Publication number Publication date
WO2008061192A3 (en) 2008-07-10
JP2010510236A (ja) 2010-04-02
EP2997973A1 (en) 2016-03-23
US20100081611A1 (en) 2010-04-01
WO2008061192A2 (en) 2008-05-22
EP2091552A2 (en) 2009-08-26
AU2007319193A1 (en) 2008-05-22
US9074009B2 (en) 2015-07-07
EP2091552A4 (en) 2010-01-06
EP2489360A1 (en) 2012-08-22
JP2014114298A (ja) 2014-06-26

Similar Documents

Publication Publication Date Title
CA2669696A1 (en) Stabilized maml peptides and uses thereof
CA2939778C (en) Stabilized p53 peptides and uses thereof
AU2011325910B2 (en) Cancer therapies and diagnostics
JP2023107892A (ja) 安定化ペプチドによって介在される標的タンパク質の分解
CN113543813B (zh) Cd38特异性的双环肽配体
JP7049989B2 (ja) Ｂｆｌ－１と結合するペプチド
JP2021501201A (ja) ステープルペプチドの細胞内送達のためのポリペプチド接合体
AU2014200485A1 (en) Stabilized maml peptides and uses thereof
AU2013231104B2 (en) Stabilized p53 peptides and uses thereof
AU2016210709A1 (en) Stabilized p53 peptides and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20160407